-
1.发明申请Methods For Assessing, Improving, Or Maintaining Urogenital Health in Postmenopausal Woman 审中-公开评估，改善或维持绝经后妇女泌尿生殖健康的方法公开(公告)号：US20100204294A1
公开(公告)日：2010-08-12
申请号：US12765298
申请日：2010-04-22
申请人： Wesley W. Day , Andrew G. Lee , David D. Thompson
发明人： Wesley W. Day , Andrew G. Lee , David D. Thompson
IPC分类号： A61K31/40
CPC分类号： A61K31/445 , A61K31/00 , A61K31/138 , A61K31/192 , A61K31/40 , A61K31/4025 , A61K31/403 , A61K31/407 , A61K31/439 , A61K31/4453 , A61K31/453 , A61K31/4535 , A61K31/55
摘要： This invention relates to methods and kits useful for improving or maintaining urogenital health using an estrogen agonist/antagonist. The methods of treatment are effective for improving or maintaining urogenital health while substantially reducing the concomitant liability of adverse effects associated with estrogen administration. This invention also relates to methods of assessing vaginal health.
摘要翻译： 本发明涉及可用于使用雌激素激动剂/拮抗剂改善或维持泌尿生殖健康的方法和试剂盒。 治疗方法对于改善或维持泌尿生殖健康是有效的，同时显着减少与雌激素给药相关的副作用的伴随责任。 本发明还涉及评估阴道健康的方法。
-
2.发明授权Pharmaceutical compositions, kits and methods comprising combinations of estrogen agonists/antagonists, estrogens and progestins 失效包含雌激素激动剂/拮抗剂，雌激素和孕激素组合的药物组合物，试剂盒和方法公开(公告)号：US07030157B2
公开(公告)日：2006-04-18
申请号：US10206587
申请日：2002-07-26
申请人： HuaZhu Ke , David D. Thompson
发明人： HuaZhu Ke , David D. Thompson
IPC分类号： A61K31/27 , A61K31/275
CPC分类号： A61K45/06 , A61K31/40 , A61K31/565 , A61K31/567 , A61K2300/00
摘要： The present invention relates to pharmaceutical compositions, kits and methods comprising combinations of (−)-cis-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydro-naphthalene-2-ol or nontoxic pharmacologically acceptable acid addition salts thereof and estrogens. The present invention also relates to pharmaceutical compositions, kits and methods comprising combinations of (−)-cis-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydro-naphthalene-2-ol or nontoxic pharmacologically acceptable acid addition salts thereof, estrogens and progestins.
摘要翻译： 本发明涉及药物组合物，试剂盒和方法，其包含（ - ） - 顺式-6-苯基-5- [4-（2-吡咯烷-1-基 - 乙氧基） - 苯基] -5,6,7， 8-四氢 - 萘-2-醇或其无毒的药理学上可接受的酸加成盐和雌激素。 本发明还涉及药物组合物，试剂盒和方法，其包括（ - ） - 顺式-6-苯基-5- [4-（2-吡咯烷-1-基 - 乙氧基） - 苯基] -5,6,7 ，8-四氢 - 萘-2-醇或其无毒的药理学上可接受的酸加成盐，雌激素和孕激素。
-
公开(公告)号：US06998423B2
公开(公告)日：2006-02-14
申请号：US10652188
申请日：2003-08-29
IPC分类号： A61K31/18 , A61K31/38 , C07C303/00 , C07D333/12
CPC分类号： C07D207/263 , A61K45/06 , C07C235/34 , C07C311/04 , C07C311/06 , C07C323/49 , C07C2601/14 , C07C2602/08 , C07D209/14 , C07D213/42 , C07D215/18 , C07D239/26 , C07D241/12 , C07D249/06 , C07D257/04 , C07D271/12 , C07D277/28 , C07D277/56 , C07D307/24 , C07D307/52 , C07D307/68 , C07D307/81 , C07D317/58 , C07D319/18 , C07D333/20 , C07D333/24 , C07D333/34 , C07D333/38 , C07D409/12
摘要： Prostaglandin agonists, methods of using such prostaglandin agonists, pharmaceutical compositions containing such prostaglandin agonists and kits containing such prostaglandin agonists. The prostaglandin agonists are useful for the treatment of bone disorders including osteoporosis.
-
4.发明授权Use of prostaglandin (PGE2) receptor a (EP4) selective agonists for the treatment of acute and chronic renal failure 失效使用前列腺素（PGE2）受体a（EP4）选择性激动剂治疗急性和慢性肾衰竭公开(公告)号：US06610719B2
公开(公告)日：2003-08-26
申请号：US09771164
申请日：2001-01-29
IPC分类号： A61K3141
CPC分类号： A61K31/00 , A61K31/4015 , A61K31/41
摘要： This invention is directed to methods and compositions of treating acute or chronic renal failure or dysfunction, or conditions caused thereby, comprising administering prostaglandin agonists, which are EP4 receptor selective prostaglandin agonists.
摘要翻译： 本发明涉及治疗急性或慢性肾衰竭或功能障碍或由此引起的病症的方法和组合物，其包括施用前列腺素激动剂，其是EP4受体选择性前列腺素激动剂。
-
公开(公告)号：US06436977B1
公开(公告)日：2002-08-20
申请号：US09656273
申请日：2000-09-06
申请人： David D. Thompson
发明人： David D. Thompson
IPC分类号： A61K31425
CPC分类号： A61K31/40
摘要： Based on lasofoxifene's half-life and potency, the drug may be dosed once per week and achieve a similar effect as if given daily.
摘要翻译： 根据拉索昔芬的半衰期和效力，每周可以给药一次，达到与日常使用相同的效果。
-
6.发明授权Prevention of loss and restoration of bone mass by certain prostaglandin agonists 失效预防某些前列腺素激动剂损失和恢复骨量公开(公告)号：US06288120B1
公开(公告)日：2001-09-11
申请号：US09331081
申请日：1999-06-11
IPC分类号： A61K3116
CPC分类号： C07D207/263 , A61K45/06 , C07C235/34 , C07C311/04 , C07C311/06 , C07C323/49 , C07C2601/14 , C07C2602/08 , C07D209/14 , C07D213/42 , C07D215/18 , C07D239/26 , C07D241/12 , C07D249/06 , C07D257/04 , C07D271/12 , C07D277/28 , C07D277/56 , C07D307/24 , C07D307/52 , C07D307/68 , C07D307/81 , C07D317/58 , C07D319/18 , C07D333/20 , C07D333/24 , C07D333/34 , C07D333/38 , C07D409/12
摘要： Prostaglandin agonists of formula (I), in which, for example, A is a sulphonyl or acyl group, B is N or CH, M contains a ring and K and Q are linking groups, methods of using such prostaglandin agonists, pharmaceutical compositions containing such prostaglandin agonists and kits useful for the treatment of bone disorders including osteoporosis.
摘要翻译： 式（I）的前列腺素激动剂，其中例如A是磺酰基或酰基，B是N或CH，M包含环，K和Q是连接基团，使用这种前列腺素激动剂的方法，含有 这种前列腺素激动剂和用于治疗包括骨质疏松症在内的骨疾病的试剂盒。
-
7.发明授权Use of estrogen antagonists and estrogen agonists in inhibiting pathological conditions 有权使用雌激素拮抗剂和雌激素激动剂来抑制病理状况公开(公告)号：US06274618B1
公开(公告)日：2001-08-14
申请号：US09314758
申请日：1999-05-19
IPC分类号： A61K3140
CPC分类号： A61K31/4725 , A61K31/40 , A61K31/4439 , A61K31/4453
摘要： The present invention provides novel methods of inhibiting pathological conditions related to organ systems which respond to estrogen agonists comprising administering to a mammal in need of such treatment an effective amount of a compound of formula I
摘要翻译： 本发明提供抑制与对雌激素激动剂作出反应的器官系统有关的病理状态的新方法，其包括对需要这种治疗的哺乳动物施用有效量的式I化合物
-
公开(公告)号：US6107331A
公开(公告)日：2000-08-22
申请号：US803733
申请日：1997-02-21
IPC分类号： C07D295/08 , A01N43/36 , A61K31/40 , A61K31/404 , A61K31/4184 , A61K31/44 , A61K31/4439 , A61K31/445 , A61K31/4453 , A61K31/454 , A61K31/46 , A61K31/47 , A61K31/4709 , A61K31/472 , A61K31/4725 , A61K31/506 , A61K31/517 , A61K31/55 , A61K31/5513 , A61P3/08 , A61P11/00 , A61P13/02 , A61P15/00 , A61P17/00 , A61P25/04 , A61P25/20 , A61P35/00 , A61P37/00 , A61P43/00 , C07D217/12
CPC分类号： A61K31/4725 , A61K31/40 , A61K31/4439 , A61K31/4453
摘要： The present invention provides novel methods of inhibiting pathological conditions related to organ systems which respond to estrogen agonists comprising administering to a mammal in need of such treatment an effective amount of a compound of formula I ##STR1##
-
9.发明授权Method of treating diseases and conditions with estrogen agonists and antagonists 失效用雌激素激动剂和拮抗剂治疗疾病和病症的方法
公开(公告)号：US5889042A
公开(公告)日：1999-03-30
申请号：US803706
申请日：1997-02-21
IPC分类号： C07D295/08 , A61K31/40 , A61K31/435 , A61K31/44 , A61K31/4439 , A61K31/445 , A61K31/4453 , A61K31/47 , A61K31/472 , A61K31/4725 , A61P9/00 , A61P13/02 , A61P15/00 , A61P25/28 , A61P37/00 , A61P43/00 , C07D217/12
CPC分类号： A61K31/4725 , A61K31/40 , A61K31/4439 , A61K31/445 , A61K31/4453
摘要： Compounds of this formula ##STR1## are useful for treating or preventing Alzheimer's disease, premenstrual syndrome, peri-menopausal syndrome, a deficiency of thrombomodulin, uterine fibrosis, excessive myeloproxidase activity, excessive thrombin, autoimmune disease, reperfusion damage of ischemic myocardium and insufficient testosterone.
摘要翻译： 该配方的化合物
可用于治疗或预防阿尔茨海默病，经前期综合征，围绝经期综合征，血栓调节素缺乏，子宫纤维化，过度骨髓过氧化物酶活性，过度凝血酶，自身免疫疾病，缺血性心肌的再灌注损伤和睾酮不足 。 -
10.发明授权Combination therapy to prevent bone loss parathyroid hormone and estrogen agonists 失效联合治疗以预防骨丢失甲状旁腺激素和雌激素激动剂
公开(公告)号：US5861438A
公开(公告)日：1999-01-19
申请号：US803712
申请日：1997-02-21
IPC分类号： A61K38/22 , A61K31/135 , A61K31/138 , A61K31/66 , A61K38/29 , A61P19/10 , A61P43/00 , A61K38/00
CPC分类号： A61K38/29 , A61K31/138 , A61B2018/00148
摘要： The present invention provides novel methods of inhibiting bone loss comprising administering to a mammal in need of such treatment an effective amount of a compound of formula I ##STR1## wherein R.sup.1 and R.sup.2 may be the same or different provided that, when R.sup.1 and R.sup.2 are the same, each is a methyl or ethyl group, and, when R.sup.1 and R.sup.2 are different, one of them is a methyl or ethyl group and the other is a hydrogen or a benzyl group; or a pharmaceutically acceptable salt thereof; together with or in combination with parathyroid hormone.
摘要翻译： 本发明提供了抑制骨丢失的新方法，其包括对需要这种治疗的哺乳动物施用有效量的式I化合物（I），其中R 1和R 2可以相同或不同，条件是当R 1 和R 2相同，各自为甲基或乙基，当R 1和R 2不同时，它们中的一个为甲基或乙基，另一个为氢或苄基; 或其药学上可接受的盐; 一起或与甲状旁腺激素组合。
-
-
-
-
-
-
-
-
-
搜索结果
52 条记录 (耗时 0.046 秒)
